ReviewInvestigational new drugs2013
Development of artemisinin compounds for cancer treatment.
Review in Investigational new drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 229 citations in OpenAlex.
- Global research on artemisinin and its derivatives: Perspectives from patents.Pharmacological research · 2020Pooled it
- Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles.RSC advances · 2026Article
- Antioxidant Food Supplementation in Cancer: Lessons from Clinical Trials and Insights from Preclinical Studies.Antioxidants (Basel, Switzerland) · 2025Review
- Advances in the Biosynthesis of Plant Terpenoids: Models, Mechanisms, and Applications.Plants (Basel, Switzerland) · 2025Review
- Review
- Supercritical COBiotechnology notes (Amsterdam, Netherlands) · 2025Review
- Investigating the Cytotoxic Effects ofBiomedicines · 2024Article
- Perturbation of hyperthermia resistance in gastric cancer by hyperstimulation of autophagy using artemisinin-protected iron-oxide nanoparticles.RSC advances · 2024Article
- New clinical application prospects of artemisinin and its derivatives: a scoping review.Infectious diseases of poverty · 2023Article
- Natural compounds targeting nuclear receptors for effective cancer therapy.Cancer metastasis reviews · 2023Review
- Molecular Hybridization as a Strategy for Developing Artemisinin-Derived Anticancer Candidates.Pharmaceutics · 2023Review
- Article
- Research Progress of Nanomedicine-Based Mild Photothermal Therapy in Tumor.International journal of nanomedicine · 2023Review
- Synthesis of Artemether-Loaded Albumin Nanoparticles and Measurement of Their Anti-Cancer Effects.Biomedicines · 2022Article
- Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels.Journal of gastrointestinal oncology · 2022Article
- Discovery and repurposing of artemisinin.Frontiers of medicine · 2022Review
- Targeting pancreatic stellate cells in chronic pancreatitis: Focus on therapeutic drugs and natural compounds.Frontiers in pharmacology · 2022Review
- Plant-derived natural products for drug discovery: current approaches and prospects.The Nucleus : an international journal of cytology and allied topics · 2022Review
- Article
- Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol.Molecules (Basel, Switzerland) · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artemisinin contains an endoperoxide moiety that can react with iron to form cytotoxic free radicals. Cancer cells contain significantly more intracellular free iron than normal cells and it has been shown that artemisinin and its analogs selectively cause apoptosis in many cancer cell lines. In addition, artemisinin compounds have been shown to have anti-angiogenic, anti-inflammatory, anti-metastasis, and growth inhibition effects. These properties make artemisinin compounds attractive cancer chemotherapeutic drug candidates. However, simple artemisinin analogs are less potent than traditional cancer chemotherapeutic agents and have short plasma half-lives, and would require high dosage and frequent administration to be effective for cancer treatment. More potent and target-selective artemisinin-compounds are being developed. These include artemisinin dimers and trimers, artemisinin hybrid compounds, and tagging of artemisinin compounds to molecules that are involved in the intracellular iron-delivery mechanism. These compounds are promising potent anticancer compounds that produce significantly less side effect than traditional chemotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.